Sample size determination for clinical trials with co‐primary outcomes: exponential event times

Clinical trials with event-time outcomes as co-primary contrasts are common in many areas such as infectious disease, oncology, and cardiovascular disease. We discuss methods for calculating the sample size for randomized superiority clinical trials with two correlated time-to-event outcomes as co-primary contrasts when the time-to-event outcomes are exponentially distributed. The approach is simple and easily applied in practice.

[1]  Ross L. Prentice,et al.  On assessing the strength of dependency between failure time variates , 1996 .

[2]  David Machin,et al.  Sample Size Tables for Clinical Studies , 1997 .

[3]  Russell D. Wolfinger,et al.  Multiple Comparisons and Multiple Tests Using the SAS System , 1999 .

[4]  N. L. Johnson,et al.  Continuous Multivariate Distributions: Models and Applications , 2005 .

[5]  Gonzalo Durán Pacheco,et al.  Multiple Testing Problems in Pharmaceutical Statistics , 2009 .

[6]  J. Lachin.  Introduction to sample size determination and power analysis for clinical trials. , 1981, Controlled clinical trials.

[7]  Philip Hougaard,et al.  Life table methods for heterogeneous populations: Distributions describing the heterogeneity , 1984 .

[8]  Toshimitsu Hamasaki,et al.  Sample size determination in clinical trials with multiple co‐primary binary endpoints , 2010, Statistics in medicine.

[9]  Jianwen Cai,et al.  Covariance and survivor function estimation using censored multivariate failure time data , 1992 .

[10]  Albrecht M. Kellerer,et al.  Small-Sample Properties of Censored-Data Rank Tests , 1983 .

[11]  E. Bluhmki,et al.  A statistical model for the dependence between progression‐free survival and overall survival , 2009, Statistics in medicine.

[12]  Hamid Pezeshk,et al.  Sample Size Determination in Clinical Trials , 1999 .

[13]  Toshimitsu Hamasaki,et al.  Sample size determination in clinical trials with multiple co‐primary endpoints including mixed continuous and binary variables , 2012, Biometrical journal. Biometrische Zeitschrift.

[14]  P. Hougaard.  A class of multivanate failure time distributions , 1986 .

[15]  R. Muirhead,et al.  Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America , 2007 .

[16]  R. Kay.  The Analysis of Survival Data , 2012 .

[17]  Elisa T. Lee,et al.  A Monte Carlo study of the power of some two-sample tests , 1975 .

[18]  Frank Bretz,et al.  Power and sample size when multiple endpoints are considered , 2007, Pharmaceutical statistics.

[19]  Christy Chuang-Stein,et al.  Challenge of multiple co‐primary endpoints: a new approach , 2007, Statistics in medicine.

[20]  M. J. Frank.  On the simultaneous associativity ofF(x, y) andx+y−F(x, y) , 1978 .

[21]  Karl E. Peace,et al.  Size and Power Assessments of Tests of Hypotheses on Survival Parameters , 1978 .

[22]  B. Everitt,et al.  Statistical methods for rates and proportions , 1973 .

[23]  C. Genest.  Frank's family of bivariate distributions , 1987 .

[24]  Sue-Jane Wang,et al.  Some Controversial Multiple Testing Problems in Regulatory Applications , 2009, Journal of biopharmaceutical statistics.

[25]  T. Hothorn,et al.  Multiple Comparisons Using R , 2010 .

[26]  Toshimitsu Hamasaki,et al.  A convenient formula for sample size calculations in clinical trials with multiple co‐primary continuous endpoints , 2012, Pharmaceutical statistics.

[27]  D. Clayton.  A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence , 1978 .

[28]  G. Rosenkranz.  Another view on the analysis of cardiovascular morbidity/mortality trials , 2011, Pharmaceutical statistics.

[29]  I. Olkin,et al.  A generalized bivariate exponential distribution , 1967 .

[30]  Toshimitsu Hamasaki,et al.  Sample Size Determination in Superiority Clinical Trials with Multiple Co-Primary Correlated Endpoints , 2011, Journal of biopharmaceutical statistics.

[31]  M. J. Frank.  On the simultaneous associativity ofF(x,y) andx +y -F(x,y) , 1979 .

[32]  I. Olkin,et al.  A Multivariate Exponential Distribution , 1967 .

[33]  R. Fletcher.  Practical Methods of Optimization , 1988 .

[34]  J Gong,et al.  Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. , 2000, Controlled clinical trials.

[35]  Peter F. Heil,et al.  Survival Distributions: Reliability Applications in the Biomedical Sciences , 1976 .

[36]  W. D. Ray.  4. Modelling Survival Data in Medical Research , 1995 .

[37]  Sin-Ho Jung,et al.  Sample size calculation for the weighted rank statistics with paired survival data , 2008, Statistics in medicine.